Water-soluble Ubiquinol Supplementation on Blood Glucose, Lipids, Oxidative Stress, and Inflammation in Diabetes

Yeh50 enrolled

Overview

Diabetes is considered an oxidative stress and a chronic inflammatory disease. Coenzyme Q10 (ubiquinone) is recognized as a lipid soluble antioxidant. Ubiquinol is a reduced form of coenzyme Q10 in our body after food or supplements intakes. Studies have indicated that the water-soluble ubiquinol had better antioxidant activity and absorption than lipid-soluble. The purpose of this study was to investigate the effects of a water-soluble ubiquinol supplement (100 mg/d) on antioxidation and anti-inflammation in diabetes patients.

The patients with type 2 diabetes will recruit as subjects (n = 50) and randomly assign to the placebo (n = 25) or coenzyme Q10 groups (n = 25). The intervention will administer for 12 weeks. The concentrations of coenzyme Q10, oxidative stress marker (malondialdehyde), antioxidant enzymes activities (superoxide dismutase, catalase, and glutathione peroxidase), inflammatory markers \[C-reactive protein (CRP), and interleukin-6 (IL-6)\], and biochemical parameters (fasting glucose, A1C, insulin, C-peptide, and lipid profiles), and blood pressure will measure. Hopefully, the results of this study could provide the information of water-soluble ubiquinol supplement for clinical doctors and dietitians recommend that diabetes patients deserve to know whether the use of coenzyme Q10 supplement.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

DOUBLE

Enrollment

Conditions

Diabetes

Interventions

water-soluble ubiquinolDIETARY_SUPPLEMENT

100 mg/d

PlaceboDIETARY_SUPPLEMENT

glycerin.soy-lecithin, and water

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The diagnostic criteria for type 2 diabetes were defined as a glycohemoglobin (A1C) ≧ 6.5%, a fasting glucose ≧ 7.0 mmol/L or a 2-h plasma glucose ≧ 200 mmol/L during an oral glucose tolerance test (OGTT), as well as the use of anti-hyperglycemic drugs. Exclusion Criteria: * pregnant or lactation women. * patients with liver or renal disease * Antioxidant dietary supplements user. * patients under warfarin therapy. * patients with hypoglycemia (fasting glucose \< 60 mg/dL) or hyperlipidemia (fasting triglyceride ≧ 500 mg/dL)

Outcomes

Primary Outcomes

Fasting glucose

serum level of fasting glucose in mmol/L.

Time frame: 12 weeks

Secondary Outcomes

Low density lipoprotein-cholesterol (LDL-C)

serum level of LDL-C in mmol/L.

Time frame: 12 weeks

high density lipoprotein-cholesterol (HDL-C)

serum level of HDL-C in mmol/L.

Time frame: 12 weeks

malondialdehyde (MDA)

plasma level of MDA in micromol/L.

Time frame: 12 weeks

catalase (CAT)

red blood cells level of CAT in Units/mg protein.

Time frame: 12 weeks

superoxide dismutase (SOD)

red blood cells level of SOD in Units/mg protein.

Time frame: 12 weeks

glutathione peroxidase (GPx)

red blood cells level of GPx in Units/mg protein.

Time frame: 12 weeks

high sensitivity C-reactive protein (hs-CRP)

serum level of hs-CRP in mg/L.

Time frame: 12 weeks

high sensitivity interleukin (hs-IL-6)

serum level of hs-IL-6 in pg/mL.

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.